CSP
BBIO icon

Cary Street Partners’s BridgeBio Pharma BBIO Stock Holding History

Cary Street Partners’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$466K Sell
6,250
-700
-10% -$49K 0.01% 689
2026
Q1 		$516K Hold
6,950
– – 0.01% 585
2025
Q4 		$532K Sell
6,950
-500
-7% -$32.8K 0.01% 586
2025
Q3 		$387K Sell
7,450
-250
-3% -$12.2K 0.01% 633
2025
Q2 		$332K Hold
7,700
– – 0.01% 643
2025
Q1 		$266K Sell
7,700
-11,660
-60% -$393K 0.01% 677
2024
Q4 		$531K Buy
+19,360
New +$500K 0.02% 500

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Cary Street Partners's BBIO Position: Q2 2026 in Review

Cary Street Partners reduced its BridgeBio Pharma (BBIO) stake by 10% in Q2 2026, selling an estimated $49K and leaving 6,250 shares worth $466K. The position accounts for 0.01% of the portfolio, ranked #689.

Cary Street Partners first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $532K in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Cary Street Partners held 6,250 shares of BridgeBio Pharma worth $466K as of Q2 2026.
  • Cary Street Partners sold 700 BridgeBio Pharma shares in Q2 2026, an estimated $49K.
  • BridgeBio Pharma made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #689 holding.
  • Cary Street Partners first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • Cary Street Partners's BridgeBio Pharma position peaked at $532K in Q4 2025.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.